Who is the worst manager at Regeneron?

Quote


































































anonymous said:
It’s really crazy!! I’ve been a top performer and leader at every company and now I have a monthly ride session like I’m in primary care!
Click to expand...
That tells me that you really aren’t all that and a bag of cats the way you think you are, or, your manager feels sorry for you and wants to spend time with you so you don’t become lonely.
 
























anonymous said:
If you actually worked here you could answer that yourself. If your a troll, keep searching
Click to expand...
Ok, Einstein... you caught me, I'm a troll. You are clearly one of the idiots who snuck past HR on your way in....

I should have clarified my question. We know the problems we'ree having with Eylea HD conversion and we know that biosimilars starting to eat up the market we built.... but come on man! Stock is down $400 in less than 3 months... is it all Eylea? Where is this company heading?
 






anonymous said:
Ok, Einstein... you caught me, I'm a troll. You are clearly one of the idiots who snuck past HR on your way in....

I should have clarified my question. We know the problems we'ree having with Eylea HD conversion and we know that biosimilars starting to eat up the market we built.... but come on man! Stock is down $400 in less than 3 months... is it all Eylea? Where is this company heading?
Click to expand...
It is still the cash cow. The price has been overinflated for years and now the big institutional investors are taking profits. It will rebound eventually based on the success of dupi
 






anonymous said:
It is still the cash cow. The price has been overinflated for years and now the big institutional investors are taking profits. It will rebound eventually based on the success of dupi
Click to expand...
Wow, someone pays attention... the only reason it's the "cash cow" is because Regeneron reports most of the revenues on Eylea (should be 100% of US and then Bayer pays royalites back to us for international). On dupi, we report profits, whereas Sanofi records revenue. It's a bit complicated but let just say our valuation is already capturing what Dupi is doing for us with something baked in on forward looking growth. In other words, Dupi might all be baked in, lest we overperform with big beats on new launches, and start converting Eylea to HD scripts. We used to get a signal that the oncology pipeline was partly baked in. Based on messaging seems Regeneron management wants the street to feel there is some magic coming in the future. Wall Street's response? You haven't proven anything yet.... And let's face it.. we must have really low performers seling Libtayo - the street expected a lot more than what that team has delivered....
 






Two day rides with so they can accrue hotel miles , air miles, rental car perks and nice meals out. Offices so do not want to see them. They bring zero value to the call or office and zero knowledge to a well tenured rep that has worked that area for many years. Providers have asked me not to bring them in. So primary care and egotistical for them to think that the offices want to see them. Sometimes , providers don’t come back because managers are there. Most of us are interviewing to save our professional reputations. Very sad. Could have been so different and successful.
 












Top Bottom
Back
Quote